Related Experiment Video
Updated: May 20, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS
M D Vincent1, M S Kuruvilla, N B Leighl
1Department of Medical Oncology, London Regional Cancer Program, London Health Sciences Centre, London, ON.
Current Oncology (Toronto, Ont.)
|July 13, 2012
Summary
Biomarkers like EGFR, ALK, and MET are crucial for targeted therapies in non-small-cell lung cancer (NSCLC). Optimizing treatment requires subgrouping patients based on these biomarkers, despite challenges in obtaining sufficient biopsy material.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advanced non-small-cell lung cancer (NSCLC) management has advanced with targeted therapies.
- New drugs include epidermal growth factor receptor (EGFR) inhibitors, ALK inhibitors, and MET inhibitors.
- Treatment benefits vary, necessitating patient subgrouping by biomarkers.
Purpose of the Study:
- To discuss the role of key biomarkers in NSCLC treatment.
- To highlight the importance of subgrouping for optimizing targeted therapy efficacy.
- To address challenges in biomarker-driven NSCLC research.
Main Methods:
- Review of current and emerging biomarkers in NSCLC.
- Analysis of biomarker roles as direct drivers or predictive indicators.
- Discussion of drug development and diagnostic companion strategies.
Main Results:
- EGFR, ALK, and MET mutations/rearrangements are key predictive biomarkers.
- KRAS mutations, while drivers, are valuable for exclusion and algorithm efficiency.
- Biomarkers predict sensitivity to targeted agents, chemotherapy, and radiotherapy.
Conclusions:
- Biomarker-driven subgrouping is essential for personalized NSCLC treatment.
- The co-development of drugs and companion diagnostics exemplifies future oncology progress.
- Obtaining adequate biopsy material remains a significant hurdle for novel targeted therapies in NSCLC.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...